Clinical Trial Detail

NCT ID NCT03829111
Title CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

clear cell renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

CBM588 + Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.